Therapeutic pyrazolyl thienopyridines
    1.
    发明授权
    Therapeutic pyrazolyl thienopyridines 有权
    治疗性吡唑并噻吩并吡啶类

    公开(公告)号:US07964612B2

    公开(公告)日:2011-06-21

    申请号:US11871311

    申请日:2007-10-12

    IPC分类号: A61K31/4365 C07D495/04

    摘要: The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGFβ-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.

    摘要翻译: 本发明提供式I化合物及其药学上可接受的盐,其中R 1,R 2,R 3,R 4,R 5,R 6和R 7具有本说明书中定义的任何值及其药学上可接受的盐, 可用作治疗TGF-bgr介导的病症,包括癌症和纤维化疾病的治疗剂。 还提供了包含一种或多种式I化合物的药物组合物。

    Therapeutic pyrazolyl thienopyridines
    2.
    发明授权
    Therapeutic pyrazolyl thienopyridines 有权
    治疗性吡唑并噻吩并吡啶类

    公开(公告)号:US08455512B2

    公开(公告)日:2013-06-04

    申请号:US13112520

    申请日:2011-05-20

    IPC分类号: A61K31/4365 C07D495/04

    摘要: The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefore in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGFβ-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.

    摘要翻译: 本发明提供式I化合物及其药学上可接受的盐,其中R 1,R 2,R 3,R 4,R 5,R 6和R 7具有在本说明书中定义的任何值及其药学上可接受的盐, 可用作治疗TGFbeta介导的病症(包括癌症和纤维化疾病)的治疗剂。 还提供了包含一种或多种式I化合物的药物组合物。

    THERAPEUTIC PYRAZOLYL THIENOPYRIDINES
    4.
    发明申请
    THERAPEUTIC PYRAZOLYL THIENOPYRIDINES 有权
    治疗性吡唑并噻唑啉酮

    公开(公告)号:US20140031385A1

    公开(公告)日:2014-01-30

    申请号:US13864457

    申请日:2013-04-17

    IPC分类号: C07D495/04

    摘要: The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGFβ-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.

    摘要翻译: 本发明提供式I化合物及其药学上可接受的盐,其中R 1,R 2,R 3,R 4,R 5,R 6和R 7具有本说明书中定义的任何值及其药学上可接受的盐, 可用作治疗TGFbeta介导的病症(包括癌症和纤维化疾病)的治疗剂。 还提供了包含一种或多种式I化合物的药物组合物。

    DIAZACARBAZOLES AND METHODS OF USE
    8.
    发明申请
    DIAZACARBAZOLES AND METHODS OF USE 审中-公开
    DIAZACARBAZOLES和使用方法

    公开(公告)号:US20110124654A1

    公开(公告)日:2011-05-26

    申请号:US12997069

    申请日:2009-06-10

    CPC分类号: C07D471/14

    摘要: The invention relates to 1,5-diazacarbazole compounds of Formula (I), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g) and (I-h) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

    摘要翻译: 本发明涉及有用的式(I),(Ia),(Ib),(Ic),(Id),(Ie),(If),(Ig)和(Ih)的1,5-二氮杂咔唑化合物 作为激酶抑制剂,更具体地用作检查点激酶1(chk1)抑制剂,因此可用作癌症治疗剂。 本发明还涉及包含这些化合物的组合物,更具体地是包含这些化合物的药物组合物以及使用该组合物治疗各种形式的癌症和过度增殖性疾病的方法,以及将该化合物用于体外,原位和体内诊断或 治疗哺乳动物细胞或相关病理状况。